Dendritic cells (DCs) refer to rare kind of leukocytes. They have prompted their recent application to therapeutic cancer vaccinations as they are uniquely effective in their ability to present antigens to T cells.

The global Dendritic Cell Cancer Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Dendritic Cell Cancer Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dendritic Cell Cancer Vaccine.

Report Scope

The Dendritic Cell Cancer Vaccine market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Dendritic Cell Cancer Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Dendritic Cell Cancer Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Dendritic Cell Cancer Vaccine Market Report

Report Metric	Details
Report Name	Dendritic Cell Cancer Vaccine Market
CAGR	5%
Segment by Type	CreaVax Sipuleucel-T (Provenge) Others
Segment by Application	Pediatrics Adults
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Activarti, Argos Therapeutics, SOTIO (Acquired by PPF Group), Bellicum Pharmaceuticals, JW CreaGene, DanDrit, DCPrime, Elios Therapeutics, ImmunoCellular Therapeutics, Kiromic, Medigene, Merck, Northwest Biotherapeutics, Immutep Limited, Dendreon Corporation, Oncobiomed
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Dendritic Cell Cancer Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Dendritic Cell Cancer Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Dendritic Cell Cancer Vaccine Market report?

Ans: The main players in the Dendritic Cell Cancer Vaccine Market are Activarti, Argos Therapeutics, SOTIO (Acquired by PPF Group), Bellicum Pharmaceuticals, JW CreaGene, DanDrit, DCPrime, Elios Therapeutics, ImmunoCellular Therapeutics, Kiromic, Medigene, Merck, Northwest Biotherapeutics, Immutep Limited, Dendreon Corporation, Oncobiomed

What are the Application segmentation covered in the Dendritic Cell Cancer Vaccine Market report?

Ans: The Applications covered in the Dendritic Cell Cancer Vaccine Market report are Pediatrics, Adults

What are the Type segmentation covered in the Dendritic Cell Cancer Vaccine Market report?

Ans: The Types covered in the Dendritic Cell Cancer Vaccine Market report are CreaVax, Sipuleucel-T (Provenge), Others

1 Dendritic Cell Cancer Vaccine Market Overview

1.1 Product Overview and Scope of Dendritic Cell Cancer Vaccine

1.2 Dendritic Cell Cancer Vaccine Segment by Type

1.2.1 Global Dendritic Cell Cancer Vaccine Market Value Comparison by Type (2024-2030)

1.2.2 CreaVax

1.2.3 Sipuleucel-T (Provenge)

1.2.4 Others

1.3 Dendritic Cell Cancer Vaccine Segment by Application

1.3.1 Global Dendritic Cell Cancer Vaccine Market Value by Application: (2024-2030)

1.3.2 Pediatrics

1.3.3 Adults

1.4 Global Dendritic Cell Cancer Vaccine Market Size Estimates and Forecasts

1.4.1 Global Dendritic Cell Cancer Vaccine Revenue 2019-2030

1.4.2 Global Dendritic Cell Cancer Vaccine Sales 2019-2030

1.4.3 Global Dendritic Cell Cancer Vaccine Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Dendritic Cell Cancer Vaccine Market Competition by Manufacturers

2.1 Global Dendritic Cell Cancer Vaccine Sales Market Share by Manufacturers (2019-2024)

2.2 Global Dendritic Cell Cancer Vaccine Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Dendritic Cell Cancer Vaccine Average Price by Manufacturers (2019-2024)

2.4 Global Dendritic Cell Cancer Vaccine Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Dendritic Cell Cancer Vaccine, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Dendritic Cell Cancer Vaccine, Product Type & Application

2.7 Dendritic Cell Cancer Vaccine Market Competitive Situation and Trends

2.7.1 Dendritic Cell Cancer Vaccine Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Dendritic Cell Cancer Vaccine Players Market Share by Revenue

2.7.3 Global Dendritic Cell Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Dendritic Cell Cancer Vaccine Retrospective Market Scenario by Region

3.1 Global Dendritic Cell Cancer Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Dendritic Cell Cancer Vaccine Global Dendritic Cell Cancer Vaccine Sales by Region: 2019-2030

3.2.1 Global Dendritic Cell Cancer Vaccine Sales by Region: 2019-2024

3.2.2 Global Dendritic Cell Cancer Vaccine Sales by Region: 2025-2030

3.3 Global Dendritic Cell Cancer Vaccine Global Dendritic Cell Cancer Vaccine Revenue by Region: 2019-2030

3.3.1 Global Dendritic Cell Cancer Vaccine Revenue by Region: 2019-2024

3.3.2 Global Dendritic Cell Cancer Vaccine Revenue by Region: 2025-2030

3.4 North America Dendritic Cell Cancer Vaccine Market Facts & Figures by Country

3.4.1 North America Dendritic Cell Cancer Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Dendritic Cell Cancer Vaccine Sales by Country (2019-2030)

3.4.3 North America Dendritic Cell Cancer Vaccine Revenue by Country (2019-2030)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Dendritic Cell Cancer Vaccine Market Facts & Figures by Country

3.5.1 Europe Dendritic Cell Cancer Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Dendritic Cell Cancer Vaccine Sales by Country (2019-2030)

3.5.3 Europe Dendritic Cell Cancer Vaccine Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Dendritic Cell Cancer Vaccine Market Facts & Figures by Country

3.6.1 Asia Pacific Dendritic Cell Cancer Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Dendritic Cell Cancer Vaccine Sales by Country (2019-2030)

3.6.3 Asia Pacific Dendritic Cell Cancer Vaccine Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Dendritic Cell Cancer Vaccine Market Facts & Figures by Country

3.7.1 Latin America Dendritic Cell Cancer Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Dendritic Cell Cancer Vaccine Sales by Country (2019-2030)

3.7.3 Latin America Dendritic Cell Cancer Vaccine Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Dendritic Cell Cancer Vaccine Market Facts & Figures by Country

3.8.1 Middle East and Africa Dendritic Cell Cancer Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Dendritic Cell Cancer Vaccine Sales by Country (2019-2030)

3.8.3 Middle East and Africa Dendritic Cell Cancer Vaccine Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Dendritic Cell Cancer Vaccine Sales by Type (2019-2030)

4.1.1 Global Dendritic Cell Cancer Vaccine Sales by Type (2019-2024)

4.1.2 Global Dendritic Cell Cancer Vaccine Sales by Type (2025-2030)

4.1.3 Global Dendritic Cell Cancer Vaccine Sales Market Share by Type (2019-2030)

4.2 Global Dendritic Cell Cancer Vaccine Revenue by Type (2019-2030)

4.2.1 Global Dendritic Cell Cancer Vaccine Revenue by Type (2019-2024)

4.2.2 Global Dendritic Cell Cancer Vaccine Revenue by Type (2025-2030)

4.2.3 Global Dendritic Cell Cancer Vaccine Revenue Market Share by Type (2019-2030)

4.3 Global Dendritic Cell Cancer Vaccine Price by Type (2019-2030)

5 Segment by Application

5.1 Global Dendritic Cell Cancer Vaccine Sales by Application (2019-2030)

5.1.1 Global Dendritic Cell Cancer Vaccine Sales by Application (2019-2024)

5.1.2 Global Dendritic Cell Cancer Vaccine Sales by Application (2025-2030)

5.1.3 Global Dendritic Cell Cancer Vaccine Sales Market Share by Application (2019-2030)

5.2 Global Dendritic Cell Cancer Vaccine Revenue by Application (2019-2030)

5.2.1 Global Dendritic Cell Cancer Vaccine Revenue by Application (2019-2024)

5.2.2 Global Dendritic Cell Cancer Vaccine Revenue by Application (2025-2030)

5.2.3 Global Dendritic Cell Cancer Vaccine Revenue Market Share by Application (2019-2030)

5.3 Global Dendritic Cell Cancer Vaccine Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Activarti

6.1.1 Activarti Corporation Information

6.1.2 Activarti Description and Business Overview

6.1.3 Activarti Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Activarti Dendritic Cell Cancer Vaccine Product Portfolio

6.1.5 Activarti Recent Developments/Updates

6.2 Argos Therapeutics

6.2.1 Argos Therapeutics Corporation Information

6.2.2 Argos Therapeutics Description and Business Overview

6.2.3 Argos Therapeutics Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Argos Therapeutics Dendritic Cell Cancer Vaccine Product Portfolio

6.2.5 Argos Therapeutics Recent Developments/Updates

6.3 SOTIO (Acquired by PPF Group)

6.3.1 SOTIO (Acquired by PPF Group) Corporation Information

6.3.2 SOTIO (Acquired by PPF Group) Description and Business Overview

6.3.3 SOTIO (Acquired by PPF Group) Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.3.4 SOTIO (Acquired by PPF Group) Dendritic Cell Cancer Vaccine Product Portfolio

6.3.5 SOTIO (Acquired by PPF Group) Recent Developments/Updates

6.4 Bellicum Pharmaceuticals

6.4.1 Bellicum Pharmaceuticals Corporation Information

6.4.2 Bellicum Pharmaceuticals Description and Business Overview

6.4.3 Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Product Portfolio

6.4.5 Bellicum Pharmaceuticals Recent Developments/Updates

6.5 JW CreaGene

6.5.1 JW CreaGene Corporation Information

6.5.2 JW CreaGene Description and Business Overview

6.5.3 JW CreaGene Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.5.4 JW CreaGene Dendritic Cell Cancer Vaccine Product Portfolio

6.5.5 JW CreaGene Recent Developments/Updates

6.6 DanDrit

6.6.1 DanDrit Corporation Information

6.6.2 DanDrit Description and Business Overview

6.6.3 DanDrit Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.6.4 DanDrit Dendritic Cell Cancer Vaccine Product Portfolio

6.6.5 DanDrit Recent Developments/Updates

6.7 DCPrime

6.6.1 DCPrime Corporation Information

6.6.2 DCPrime Description and Business Overview

6.6.3 DCPrime Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.4.4 DCPrime Dendritic Cell Cancer Vaccine Product Portfolio

6.7.5 DCPrime Recent Developments/Updates

6.8 Elios Therapeutics

6.8.1 Elios Therapeutics Corporation Information

6.8.2 Elios Therapeutics Description and Business Overview

6.8.3 Elios Therapeutics Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Elios Therapeutics Dendritic Cell Cancer Vaccine Product Portfolio

6.8.5 Elios Therapeutics Recent Developments/Updates

6.9 ImmunoCellular Therapeutics

6.9.1 ImmunoCellular Therapeutics Corporation Information

6.9.2 ImmunoCellular Therapeutics Description and Business Overview

6.9.3 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.9.4 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Product Portfolio

6.9.5 ImmunoCellular Therapeutics Recent Developments/Updates

6.10 Kiromic

6.10.1 Kiromic Corporation Information

6.10.2 Kiromic Description and Business Overview

6.10.3 Kiromic Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Kiromic Dendritic Cell Cancer Vaccine Product Portfolio

6.10.5 Kiromic Recent Developments/Updates

6.11 Medigene

6.11.1 Medigene Corporation Information

6.11.2 Medigene Dendritic Cell Cancer Vaccine Description and Business Overview

6.11.3 Medigene Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.11.4 Medigene Dendritic Cell Cancer Vaccine Product Portfolio

6.11.5 Medigene Recent Developments/Updates

6.12 Merck

6.12.1 Merck Corporation Information

6.12.2 Merck Dendritic Cell Cancer Vaccine Description and Business Overview

6.12.3 Merck Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.12.4 Merck Dendritic Cell Cancer Vaccine Product Portfolio

6.12.5 Merck Recent Developments/Updates

6.13 Northwest Biotherapeutics

6.13.1 Northwest Biotherapeutics Corporation Information

6.13.2 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Description and Business Overview

6.13.3 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.13.4 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Product Portfolio

6.13.5 Northwest Biotherapeutics Recent Developments/Updates

6.14 Immutep Limited

6.14.1 Immutep Limited Corporation Information

6.14.2 Immutep Limited Dendritic Cell Cancer Vaccine Description and Business Overview

6.14.3 Immutep Limited Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.14.4 Immutep Limited Dendritic Cell Cancer Vaccine Product Portfolio

6.14.5 Immutep Limited Recent Developments/Updates

6.15 Dendreon Corporation

6.15.1 Dendreon Corporation Corporation Information

6.15.2 Dendreon Corporation Dendritic Cell Cancer Vaccine Description and Business Overview

6.15.3 Dendreon Corporation Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.15.4 Dendreon Corporation Dendritic Cell Cancer Vaccine Product Portfolio

6.15.5 Dendreon Corporation Recent Developments/Updates

6.16 Oncobiomed

6.16.1 Oncobiomed Corporation Information

6.16.2 Oncobiomed Dendritic Cell Cancer Vaccine Description and Business Overview

6.16.3 Oncobiomed Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.16.4 Oncobiomed Dendritic Cell Cancer Vaccine Product Portfolio

6.16.5 Oncobiomed Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Dendritic Cell Cancer Vaccine Industry Chain Analysis

7.2 Dendritic Cell Cancer Vaccine Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Dendritic Cell Cancer Vaccine Production Mode & Process

7.4 Dendritic Cell Cancer Vaccine Sales and Marketing

7.4.1 Dendritic Cell Cancer Vaccine Sales Channels

7.4.2 Dendritic Cell Cancer Vaccine Distributors

7.5 Dendritic Cell Cancer Vaccine Customers

8 Dendritic Cell Cancer Vaccine Market Dynamics

8.1 Dendritic Cell Cancer Vaccine Industry Trends

8.2 Dendritic Cell Cancer Vaccine Market Drivers

8.3 Dendritic Cell Cancer Vaccine Market Challenges

8.4 Dendritic Cell Cancer Vaccine Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Activarti

Argos Therapeutics

Bellicum Pharmaceuticals

Northwest Biotherapeutics

SOTIO (Acquired by PPF Group)

JW CreaGene

DanDrit

ImmunoCellular Therapeutics

List of Tables

Table 1. Global Dendritic Cell Cancer Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Dendritic Cell Cancer Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Dendritic Cell Cancer Vaccine Market Competitive Situation by Manufacturers in 2023

Table 4. Global Dendritic Cell Cancer Vaccine Sales (Units) of Key Manufacturers (2019-2024)

Table 5. Global Dendritic Cell Cancer Vaccine Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Dendritic Cell Cancer Vaccine Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Dendritic Cell Cancer Vaccine Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Dendritic Cell Cancer Vaccine Average Price (USD/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Dendritic Cell Cancer Vaccine, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Dendritic Cell Cancer Vaccine, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Dendritic Cell Cancer Vaccine, Product Type & Application

Table 12. Global Key Manufacturers of Dendritic Cell Cancer Vaccine, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Dendritic Cell Cancer Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dendritic Cell Cancer Vaccine as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Dendritic Cell Cancer Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Dendritic Cell Cancer Vaccine Sales by Region (2019-2024) & (Units)

Table 18. Global Dendritic Cell Cancer Vaccine Sales Market Share by Region (2019-2024)

Table 19. Global Dendritic Cell Cancer Vaccine Sales by Region (2025-2030) & (Units)

Table 20. Global Dendritic Cell Cancer Vaccine Sales Market Share by Region (2025-2030)

Table 21. Global Dendritic Cell Cancer Vaccine Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Dendritic Cell Cancer Vaccine Revenue Market Share by Region (2019-2024)

Table 23. Global Dendritic Cell Cancer Vaccine Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Dendritic Cell Cancer Vaccine Revenue Market Share by Region (2025-2030)

Table 25. North America Dendritic Cell Cancer Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Dendritic Cell Cancer Vaccine Sales by Country (2019-2024) & (Units)

Table 27. North America Dendritic Cell Cancer Vaccine Sales by Country (2025-2030) & (Units)

Table 28. North America Dendritic Cell Cancer Vaccine Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Dendritic Cell Cancer Vaccine Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Dendritic Cell Cancer Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Dendritic Cell Cancer Vaccine Sales by Country (2019-2024) & (Units)

Table 32. Europe Dendritic Cell Cancer Vaccine Sales by Country (2025-2030) & (Units)

Table 33. Europe Dendritic Cell Cancer Vaccine Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Dendritic Cell Cancer Vaccine Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Dendritic Cell Cancer Vaccine Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Dendritic Cell Cancer Vaccine Sales by Region (2019-2024) & (Units)

Table 37. Asia Pacific Dendritic Cell Cancer Vaccine Sales by Region (2025-2030) & (Units)

Table 38. Asia Pacific Dendritic Cell Cancer Vaccine Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Dendritic Cell Cancer Vaccine Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Dendritic Cell Cancer Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Dendritic Cell Cancer Vaccine Sales by Country (2019-2024) & (Units)

Table 42. Latin America Dendritic Cell Cancer Vaccine Sales by Country (2025-2030) & (Units)

Table 43. Latin America Dendritic Cell Cancer Vaccine Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Dendritic Cell Cancer Vaccine Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Dendritic Cell Cancer Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Dendritic Cell Cancer Vaccine Sales by Country (2019-2024) & (Units)

Table 47. Middle East & Africa Dendritic Cell Cancer Vaccine Sales by Country (2025-2030) & (Units)

Table 48. Middle East & Africa Dendritic Cell Cancer Vaccine Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Dendritic Cell Cancer Vaccine Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Dendritic Cell Cancer Vaccine Sales (Units) by Type (2019-2024)

Table 51. Global Dendritic Cell Cancer Vaccine Sales (Units) by Type (2025-2030)

Table 52. Global Dendritic Cell Cancer Vaccine Sales Market Share by Type (2019-2024)

Table 53. Global Dendritic Cell Cancer Vaccine Sales Market Share by Type (2025-2030)

Table 54. Global Dendritic Cell Cancer Vaccine Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Dendritic Cell Cancer Vaccine Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Dendritic Cell Cancer Vaccine Revenue Market Share by Type (2019-2024)

Table 57. Global Dendritic Cell Cancer Vaccine Revenue Market Share by Type (2025-2030)

Table 58. Global Dendritic Cell Cancer Vaccine Price (USD/Unit) by Type (2019-2024)

Table 59. Global Dendritic Cell Cancer Vaccine Price (USD/Unit) by Type (2025-2030)

Table 60. Global Dendritic Cell Cancer Vaccine Sales (Units) by Application (2019-2024)

Table 61. Global Dendritic Cell Cancer Vaccine Sales (Units) by Application (2025-2030)

Table 62. Global Dendritic Cell Cancer Vaccine Sales Market Share by Application (2019-2024)

Table 63. Global Dendritic Cell Cancer Vaccine Sales Market Share by Application (2025-2030)

Table 64. Global Dendritic Cell Cancer Vaccine Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Dendritic Cell Cancer Vaccine Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Dendritic Cell Cancer Vaccine Revenue Market Share by Application (2019-2024)

Table 67. Global Dendritic Cell Cancer Vaccine Revenue Market Share by Application (2025-2030)

Table 68. Global Dendritic Cell Cancer Vaccine Price (USD/Unit) by Application (2019-2024)

Table 69. Global Dendritic Cell Cancer Vaccine Price (USD/Unit) by Application (2025-2030)

Table 70. Activarti Corporation Information

Table 71. Activarti Description and Business Overview

Table 72. Activarti Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 73. Activarti Dendritic Cell Cancer Vaccine Product

Table 74. Activarti Recent Developments/Updates

Table 75. Argos Therapeutics Corporation Information

Table 76. Argos Therapeutics Description and Business Overview

Table 77. Argos Therapeutics Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 78. Argos Therapeutics Dendritic Cell Cancer Vaccine Product

Table 79. Argos Therapeutics Recent Developments/Updates

Table 80. SOTIO (Acquired by PPF Group) Corporation Information

Table 81. SOTIO (Acquired by PPF Group) Description and Business Overview

Table 82. SOTIO (Acquired by PPF Group) Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 83. SOTIO (Acquired by PPF Group) Dendritic Cell Cancer Vaccine Product

Table 84. SOTIO (Acquired by PPF Group) Recent Developments/Updates

Table 85. Bellicum Pharmaceuticals Corporation Information

Table 86. Bellicum Pharmaceuticals Description and Business Overview

Table 87. Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 88. Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Product

Table 89. Bellicum Pharmaceuticals Recent Developments/Updates

Table 90. JW CreaGene Corporation Information

Table 91. JW CreaGene Description and Business Overview

Table 92. JW CreaGene Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 93. JW CreaGene Dendritic Cell Cancer Vaccine Product

Table 94. JW CreaGene Recent Developments/Updates

Table 95. DanDrit Corporation Information

Table 96. DanDrit Description and Business Overview

Table 97. DanDrit Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 98. DanDrit Dendritic Cell Cancer Vaccine Product

Table 99. DanDrit Recent Developments/Updates

Table 100. DCPrime Corporation Information

Table 101. DCPrime Description and Business Overview

Table 102. DCPrime Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 103. DCPrime Dendritic Cell Cancer Vaccine Product

Table 104. DCPrime Recent Developments/Updates

Table 105. Elios Therapeutics Corporation Information

Table 106. Elios Therapeutics Description and Business Overview

Table 107. Elios Therapeutics Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 108. Elios Therapeutics Dendritic Cell Cancer Vaccine Product

Table 109. Elios Therapeutics Recent Developments/Updates

Table 110. ImmunoCellular Therapeutics Corporation Information

Table 111. ImmunoCellular Therapeutics Description and Business Overview

Table 112. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 113. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Product

Table 114. ImmunoCellular Therapeutics Recent Developments/Updates

Table 115. Kiromic Corporation Information

Table 116. Kiromic Description and Business Overview

Table 117. Kiromic Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 118. Kiromic Dendritic Cell Cancer Vaccine Product

Table 119. Kiromic Recent Developments/Updates

Table 120. Medigene Corporation Information

Table 121. Medigene Description and Business Overview

Table 122. Medigene Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 123. Medigene Dendritic Cell Cancer Vaccine Product

Table 124. Medigene Recent Developments/Updates

Table 125. Merck Corporation Information

Table 126. Merck Description and Business Overview

Table 127. Merck Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 128. Merck Dendritic Cell Cancer Vaccine Product

Table 129. Merck Recent Developments/Updates

Table 130. Northwest Biotherapeutics Corporation Information

Table 131. Northwest Biotherapeutics Description and Business Overview

Table 132. Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 133. Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Product

Table 134. Northwest Biotherapeutics Recent Developments/Updates

Table 135. Immutep Limited Corporation Information

Table 136. Immutep Limited Description and Business Overview

Table 137. Immutep Limited Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 138. Immutep Limited Dendritic Cell Cancer Vaccine Product

Table 139. Immutep Limited Recent Developments/Updates

Table 140. Dendreon Corporation Corporation Information

Table 141. Dendreon Corporation Description and Business Overview

Table 142. Dendreon Corporation Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 143. Dendreon Corporation Dendritic Cell Cancer Vaccine Product

Table 144. Dendreon Corporation Recent Developments/Updates

Table 145. Oncobiomed Corporation Information

Table 146. Oncobiomed Description and Business Overview

Table 147. Oncobiomed Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 148. Oncobiomed Dendritic Cell Cancer Vaccine Product

Table 149. Oncobiomed Recent Developments/Updates

Table 150. Key Raw Materials Lists

Table 151. Raw Materials Key Suppliers Lists

Table 152. Dendritic Cell Cancer Vaccine Distributors List

Table 153. Dendritic Cell Cancer Vaccine Customers List

Table 154. Dendritic Cell Cancer Vaccine Market Trends

Table 155. Dendritic Cell Cancer Vaccine Market Drivers

Table 156. Dendritic Cell Cancer Vaccine Market Challenges

Table 157. Dendritic Cell Cancer Vaccine Market Restraints

Table 158. Research Programs/Design for This Report

Table 159. Key Data Information from Secondary Sources

Table 160. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Dendritic Cell Cancer Vaccine

Figure 2. Global Dendritic Cell Cancer Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Dendritic Cell Cancer Vaccine Market Share by Type in 2023 & 2030

Figure 4. CreaVax Product Picture

Figure 5. Sipuleucel-T (Provenge) Product Picture

Figure 6. Others Product Picture

Figure 7. Global Dendritic Cell Cancer Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 8. Global Dendritic Cell Cancer Vaccine Market Share by Application in 2023 & 2030

Figure 9. Pediatrics

Figure 10. Adults

Figure 11. Global Dendritic Cell Cancer Vaccine Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 12. Global Dendritic Cell Cancer Vaccine Market Size (2019-2030) & (US$ Million)

Figure 13. Global Dendritic Cell Cancer Vaccine Sales (2019-2030) & (Units)

Figure 14. Global Dendritic Cell Cancer Vaccine Average Price (USD/Unit) & (2019-2030)

Figure 15. Dendritic Cell Cancer Vaccine Report Years Considered

Figure 16. Dendritic Cell Cancer Vaccine Sales Share by Manufacturers in 2023

Figure 17. Global Dendritic Cell Cancer Vaccine Revenue Share by Manufacturers in 2023

Figure 18. The Global 5 and 10 Largest Dendritic Cell Cancer Vaccine Players: Market Share by Revenue in 2023

Figure 19. Dendritic Cell Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 20. Global Dendritic Cell Cancer Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 21. North America Dendritic Cell Cancer Vaccine Sales Market Share by Country (2019-2030)

Figure 22. North America Dendritic Cell Cancer Vaccine Revenue Market Share by Country (2019-2030)

Figure 23. U.S. Dendritic Cell Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 24. Canada Dendritic Cell Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 25. Europe Dendritic Cell Cancer Vaccine Sales Market Share by Country (2019-2030)

Figure 26. Europe Dendritic Cell Cancer Vaccine Revenue Market Share by Country (2019-2030)

Figure 27. Germany Dendritic Cell Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 28. France Dendritic Cell Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. U.K. Dendritic Cell Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. Italy Dendritic Cell Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. Russia Dendritic Cell Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Asia Pacific Dendritic Cell Cancer Vaccine Sales Market Share by Region (2019-2030)

Figure 33. Asia Pacific Dendritic Cell Cancer Vaccine Revenue Market Share by Region (2019-2030)

Figure 34. China Dendritic Cell Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 35. Japan Dendritic Cell Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. South Korea Dendritic Cell Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. India Dendritic Cell Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. Australia Dendritic Cell Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. Taiwan Dendritic Cell Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Indonesia Dendritic Cell Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Thailand Dendritic Cell Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Malaysia Dendritic Cell Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Philippines Dendritic Cell Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Latin America Dendritic Cell Cancer Vaccine Sales Market Share by Country (2019-2030)

Figure 45. Latin America Dendritic Cell Cancer Vaccine Revenue Market Share by Country (2019-2030)

Figure 46. Mexico Dendritic Cell Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 47. Brazil Dendritic Cell Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Argentina Dendritic Cell Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. Middle East & Africa Dendritic Cell Cancer Vaccine Sales Market Share by Country (2019-2030)

Figure 50. Middle East & Africa Dendritic Cell Cancer Vaccine Revenue Market Share by Country (2019-2030)

Figure 51. Turkey Dendritic Cell Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 52. Saudi Arabia Dendritic Cell Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 53. U.A.E Dendritic Cell Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 54. Global Sales Market Share of Dendritic Cell Cancer Vaccine by Type (2019-2030)

Figure 55. Global Revenue Market Share of Dendritic Cell Cancer Vaccine by Type (2019-2030)

Figure 56. Global Dendritic Cell Cancer Vaccine Price (USD/Unit) by Type (2019-2030)

Figure 57. Global Sales Market Share of Dendritic Cell Cancer Vaccine by Application (2019-2030)

Figure 58. Global Revenue Market Share of Dendritic Cell Cancer Vaccine by Application (2019-2030)

Figure 59. Global Dendritic Cell Cancer Vaccine Price (USD/Unit) by Application (2019-2030)

Figure 60. Dendritic Cell Cancer Vaccine Value Chain

Figure 61. Dendritic Cell Cancer Vaccine Production Process

Figure 62. Channels of Distribution (Direct Vs Distribution)

Figure 63. Distributors Profiles

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions